Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceuticals industry.
Teva Pharmaceutical Industries Limited ( TEVA ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies.
Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd.
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ethic Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 7.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,490 shares of the company's stock after selling 1,399 shares during the quarter. Ethic Inc.'s holdings in